1. Home
  2. CNTN vs ALXO Comparison

CNTN vs ALXO Comparison

Compare CNTN & ALXO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Canton Strategic Holdings Inc. Common Stock

CNTN

Canton Strategic Holdings Inc. Common Stock

N/A

Current Price

$1.91

Market Cap

153.8M

Sector

Health Care

ML Signal

N/A

Logo ALX Oncology Holdings Inc.

ALXO

ALX Oncology Holdings Inc.

N/A

Current Price

$1.16

Market Cap

172.8M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
CNTN
ALXO
Founded
2017
2015
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
153.8M
172.8M
IPO Year
2021
2020

Fundamental Metrics

Financial Performance
Metric
CNTN
ALXO
Price
$1.91
$1.16
Analyst Decision
Strong Buy
Analyst Count
0
7
Target Price
N/A
★ $4.60
AVG Volume (30 Days)
653.1K
★ 1.4M
Earning Date
11-24-2026
11-24-2026
Dividend Yield
N/A
N/A
EPS Growth
★ 88.10
26.36
EPS
★ N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
★ N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.66
$0.86
52 Week High
$5.27
$2.66

Technical Indicators

Market Signals
Indicator
CNTN
ALXO
Relative Strength Index (RSI) 46.56 46.32
Support Level $1.71 $1.03
Resistance Level $2.21 $1.34
Average True Range (ATR) 0.16 0.14
MACD 0.01 0.01
Stochastic Oscillator 28.57 35.90

Price Performance

Historical Comparison
CNTN
ALXO

About CNTN Canton Strategic Holdings Inc. Common Stock

Canton Strategic Holdings Inc is engaged in activities related to Canton Network, including the use of Canton Coin, to support blockchain-based infrastructure and the digitization of financial market processes. The company operates in two reportable segments: digital asset treasury and clinical stage bio-technology. Its flagship clinical asset, GV104, is being developed for a specific indication for respiratory and/or nervous system depression in military personnel and chemical incident responders. The expanded pipeline includes other indications for GV104 and GV023, an approach to autoimmune diseases as well as an early-stage multispecific biologic platform.

About ALXO ALX Oncology Holdings Inc.

ALX Oncology Holdings Inc is a clinical-stage immuno-oncology company focused on helping patients fight cancer by developing a pipeline of product candidates based on expertise in protein engineering and oncology led by the CD47 blocker, evorpacept, currently in phase 1 and 2 clinical trials. Cancer cells leverage CD47, a cell surface protein, as a don't eat me signal to evade detection by the immune system. It is developing a next-generation checkpoint inhibitor designed to have a high affinity for CD47 and to avoid the limitations caused by hematologic toxicities inherent in other CD47 blocking approaches.

Share on Social Networks: